Amytrx Therapeutics develops AMTX-100, a first-in-class cell-penetrating peptide therapeutic that targets importins to modulate inflammation at the intracellular level. This approach aims to reduce the pathogenesis of chronic inflammatory diseases, with an initial focus on treating atopic dermatitis.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammatory diseases are driven by excessive and uncontrolled inflammation, leading to significant pathogenesis. Current treatments often fail to address the intracellular mechanisms that initiate and propagate inflammation. This results in limited efficacy and the potential for significant side effects.
Solution
Amytrx Therapeutics is developing AMTX-100, a first-in-class cell-penetrating peptide therapeutic designed to modulate inflammation at the intracellular level by targeting importins. AMTX-100 is bioengineered from human protein sequences and selectively attenuates the intracellular molecular machinery of immune cells, easing inflammation early in the process, before gene activation. This approach aims to reduce the pathogenesis of a range of chronic inflammatory diseases. AMTX-100's patented delivery system has demonstrated safety, tolerance, and efficacy in preclinical and clinical studies.
Target Audience
The primary target audience includes patients suffering from chronic inflammatory diseases, with an initial focus on dermatologic conditions such as atopic dermatitis.
Features
- Cell-penetrating peptide technology enables intracellular delivery of the therapeutic.
- Targets importins, a novel intracellular target for modulating inflammation.
- Bioengineered from human protein sequences for enhanced biocompatibility.
- Modulates the immune system through a selective, natural process.
- Demonstrated safety, tolerance, and efficacy in preclinical and clinical studies.
- Potential to overcome a range of chronic diseases caused by inflammation.